Phase I Studies in Patient Populations:
De-risking Clinical Development by Obtaining Key Patient Data Earlier
About this webinar
In this webinar, members of Simbec-Orion’s specialist early phase Project Management team will discuss how they tackled a range of challenges to successfully execute a variety of Phase I clinical studies in patient populations.
Attendees will learn how different regulatory and operational strategies were employed to optimise trial efficiency, minimise regulatory review timeframes and maximise recruitment efforts of early phase patient studies. These will be demonstrated via a number of case studies including:
- A First-into-Human study combining healthy volunteer and rare disease patient population parts within the same protocol
- A human pharmacology study involving patients with neurodegenerative disease
- A gamma-scintigraphy imaging/inhaled drug lung distribution study in patients with moderate and severe chronic obstructive pulmonary disease (COPD)
Who should attend
Drug developers with assets in pre-clinical development – aiming to go into early phase I/II research in the next 12 – 18 months Director level in the following job titles:
- Clinical development
- Clinical operations
- Procurement
- Translational medicine
- Clinical pharmacology
What you will learn
- Regulatory strategies to minimize review timeframes and maximize recruitment efforts
- The importance of operational excellence to increase trial efficiency
Featured Speakers
Nadine Aawar
Nadine Aawar is experienced in developing, implementing and managing phase I bioavailability/PK studies and investigator – led phase II and phase III multi-centre publicly and commercially-sponsored trials in different study populations and settings (children and young people, infections, dental, GP Practices, secondary and primary care). Nadine obtained a PhD in Clinical Pharmacy from Cardiff University and also holds an MPharm.
Laura Llewellyn
Laura Llewellyn joined Simbec-Orion in November 2018. Laura has extensive experience in the development, implementation and execution of multi-center clinical trials. Following completion of her PhD at the University of Oxford, Laura joined the Cancer Research UK Clinical Trials Unit at the University of Birmingham where she managed a team of clinical research professionals to deliver early phase trials sponsored by both academic and commercial organizations. During this time, Laura undertook a postgraduate diploma in Clinical Oncology. In addition, Laura holds an MSc in Biomedical Science and a BSc in Biology.
Laura Galligan
Laura Galligan joined Simbec-Orion in September 2017 from the Welsh Ambulance Service where she has supported the growth of pre-hospital research in Wales and facilitated the conduct of numerous trials for cardiac arrest, stroke, transient ischaemic attacks and hip fractures. Laura has over 3 years of research experience within the National Health Service (NHS) that has included a role of Clinical Trials Coordinator for the Aneurin Bevan University Health Board. This role required Laura to coordinate and facilitate commercial and non-commercial trials across a number of specialities including oncology, respiratory, surgical and emergency care. Laura uses her NHS experience to support the growth of patient trials at Simbec-Orion.
Partner for this event
Simbec-Orion
Simbec-Orion is a full service international CRO focused on oncology, rare disease and healthy volunteer studies. We offer our clients a full spectrum of drug development services from first-in-human Phase I clinical studies through to pivotal Phase III studies and Phase IV post marketing studies. We have expertise in all drug types, dosage forms and delivery mechanisms. Established in 1976, our experience and expertise enables us to become a true ally on your drug development journey.
Related webinars
More from Simbec-Orion.
Embedding Neuroscience Techniques to Measure Target Engagement in First-In-Human CNS Clinical Trials
Utilising a Virtual Central Laboratory Approach to Balance the Delivery, Budget and Risk for Clinical Trials
Accelerate Early Clinical Development with Adaptive, Multi-Part, First-in-Human Study Design
Meeting the Needs of Rare Disease Patients in Clinical Trials During the COVID-19 Pandemic
Time for a Clinical Trial Revolution – Complex Innovative Design (CID) Cancer Trials
Agility in Rare Disease and Oncology Clinical Trials – Data Management
Providing Critical Data in Early Clinical Development with Scintigraphy
ESMO Update: State of the Art in Early Phase Oncology Trial Design
Orphan Drug Designation: Meeting the Unmet Need in Rare Diseases
Effective Implementation of the Revised EMA First-in-Human (FIH) Guidance to Accelerate Your Early Clinical Development
Conducting Early Phase Oncology Studies – Successfully Moving Through to Proof of Concept and Beyond
Rare Disease & Orphan Drug Development: Cost-Efficient Trial Design to Minimize Cash Burn
